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Here, we describe a new HLA-B*3501-restricted cytotoxic T lymphocyte (CTL) epitope in the influenza A
virus (H3N2) nucleoprotein, which was found to exhibit a high degree of variation at nonanchor residues. The
influenza virus variants emerged in chronological order, and CTLs directed against old variants failed to
recognize more recent strains of influenza A virus, indicating an escape from CTL immunity.
CD8 cytotoxic T lymphocytes (CTLs) contribute to the
control of viral infections by recognizing antigenic peptides of
viral proteins presented by major histocompatibility complex
(MHC) class I molecules on infected cells. The specific recog-
nition of these MHC-peptide complexes by CTLs may lead to
the elimination of virus-infected cells. One of the mechanisms
exploited by viruses to evade recognition by CTLs (19, 23, 28)
involves antigenic variation in CTL epitopes or mutations in
sequences flanking these epitopes. Antigenic variation in CTL
epitopes, resulting in the evasion of immune surveillance by
specific CTLs, has been described for several viruses that cause
chronic infections, including Epstein-Barr virus (5, 8, 9, 12),
human immunodeficiency virus (4, 7, 13, 14, 22, 26), hepatitis
B virus (1, 2), and hepatitis C virus (6, 35).
Recently, mutations were also found at the anchor residue of
an HLA-B*2705-restricted epitope of the influenza A virus
nucleoprotein (NP), which consisted of amino acids 383 to 391
(NP383-391). Both the R384G and the R384K mutations abol-
ished class I-restricted presentation and allowed for escape
from CTL recognition (34). Thus, these viruses, which cause
acute infections in a significant portion of the human popula-
tion annually, can escape from immune surveillance by CTLs
in addition to escaping from neutralizing antibodies (antigenic
drift and antigenic shift).
For the identification of new CTL epitopes, CD3- and
CD8-T-cell clones were generated by limiting dilution (34)
from the peripheral blood mononuclear cells (PBMC) of an
HLA-A*0101-, HLA-A*0201-, HLA-B*0801-, and HLA-
B*3501-positive donor after in vitro stimulation with influenza
virus Resvir-9, a reassortant vaccine strain of A/Nanchang/
933/95 (3). For the initial specificity testing of the T-cell clones,
an enzyme-linked immunospot assay was used, as described
previously (3), with cells from the infected autologous B-lym-
phoblastoid cell line (BLCL) as stimulator cells. Clone 1980-1
was found to recognize a yet unidentified epitope in an HLA-
B*3501- and HLA-B*3503-restricted fashion, as demonstrated
with cells from the HLA-matching and -nonmatching infected
BLCL as target cells (Fig. 1A; also data not shown). This clone
was specific for the NP of influenza A virus (H3N2), since it
lysed target cells incubated with recombinant NP (rNP) (Fig.
1B), as described previously (3, 33). By using a CTL epitope
prediction program (25) (http://www.umds.ac.uk/tissue), puta-
tive HLA-B*3501-restricted epitopes in the NP of influenza A
virus (H3N2) were predicted. The 9-mer with the highest rank-
ing, LPFEKSTVM (NP418-426/1980), was synthesized and was
found to be recognized by the T-cell clone 1980-1 in a CTL
assay (Fig. 1C). Removal of the C-terminal methionine abol-
ished recognition by clone 1980-1 (Fig. 1D). A similar result
was observed when the lysine at the N terminus of the 9-mer
epitope LPFEKSTVM was removed. Addition of one amino
acid at the N or C terminus of the epitope did not significantly
improve recognition of target cells, indicating that NP418-426
was the minimal epitope.
Experiments with rNPs from different virus strains indicated
that clone 1980-1 did not react with the rNP obtained from
A/Hong Kong/2/68 (H3N2) (data not shown). Therefore,
known NP418-426 sequences of influenza A viruses obtained
from the influenza sequence database (http://www.flu.lanl.gov)
were compared. It was found that the amino acid sequence in
the epitope varied at four positions and that these variants
emerged in chronological order. All variants and their desig-
nations are shown in Table 1. Although the strains used for NP
sequence comparison were not controlled for passage history
of the strains (eggs grown or passaged in mammalian cell
lines), it is unlikely that this has biased the analysis, since no
immediate selective pressure on the NP was observed by ad-
aptation in eggs, as was the case for the hemagglutinin (29).
A T2 cell line expressing HLA-B*3501 (30) was used to
assess the affinity of the NP418-426 epitopes for the HLA-
B*3501 molecule as previously described (32). The concentra-
tion of peptide necessary to inhibit the signal (mean fluores-
cence intensity [MFI]) of the fluorescein isothiocyanate-
labeled reference peptide LPSCFLADVEF (20) by 50% (IC50)
was determined. The mean IC50 of the NP418-426/1980 epitope
was 1.1 M, while the mean IC50s of the NP418-426/1972 and
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NP418-426/1957 epitopes were 1.5 and 1.6 M, respectively; this
indicates that all three epitopes bound strongly and in the same
order of magnitude to HLA-B*3501 (Table 2), which suggests
that the three peptides represent CTL epitopes. For compar-
ison, the IC50 of a previously described HLA-B35-restricted
influenza A virus epitope, M1128-135, was determined and
found to be higher than the highest concentration used (20
M).
The frequency of peptide-specific CTL precursors was de-
termined for the NP418-426/1980, NP418-426/1972, and
NP418-426/1957 variants of the epitope and found to differ con-
siderably among four HLA-B35 donors (Table 3). The aver-
age frequency of NP418-426/1980-specific cells was 1 in 7,426,
ranging from 1 in 4,073 to 1 in 15,485, which is relatively high
compared to the frequencies of other CTL epitopes of influ-
enza A virus (3), indicating that NP418-426/1980 is an immuno-
FIG. 1. Characterization of an HLA-B*3501-restricted epitope and CTL clone (1980-1). (A) HLA class I restriction of CTL clone 1980-1 was
determined by partially mismatched target cells (BLCL) infected with influenza A (H3N2) virus (Resvir-9) in a 51Cr release assay at effector-to-
target cell (E:T) ratios of 10:1 (black bars) and 5:1 (grey bars) as described previously (3). Autologous BLCL cells (HLA-A*0101, HLA-A*0201,
HLA-B*0801, and HLA-B*3501) and BLCL cells mismatched for a single HLA class I molecule (HLA-A*0101, HLA-A*0201, and HLA-
B*3501) were used. All BLCL cells expressed HLA-B*0801. The percent lysis of uninfected target cells was subtracted from the percent lysis of
target cells infected with influenza virus. (B) Protein specificity of an HLA-B*3501-restricted CTL clone. HLA-B*3501 target cells were infected
with influenza A (H3N2) virus (Resvir-9) or were left uninfected and used as positive and negative controls, respectively. In addition, HLA-
B*3501 target cells were incubated overnight with 100 g of bacterially expressed rNP of A/Netherlands/18/94 (A/H3N2)/ml as previously
described (33). The target cells were used in a 51Cr release assay with CTL clone 1980-1 at E:T ratios of 10:1 (black bars) and 5:1 (grey bars). (C) A
9-mer peptide (NP418-426; LPFEKSTVM) (ƒ), predicted with an HLA binding prediction program (25), was loaded onto HLA-B*3501
 BLCL
cells and used as target cells in a 51Cr release assay with the T-cell clone 1980-1 at the indicated E:T ratios. Untreated BLCL cells (F) were included
as a negative control. (D) Minimal epitope mapping of HLA-B*3501-restricted epitope. Peptides were synthesized based on the initial 9-amino-
acid sequence LPFEKSTVM that was extended or truncated at the C- or N-terminal end of the NP418-426 epitope in order to determine the minimal
epitope. BLCL cells loaded with 5 M concentrations of the different peptides were used as target cells in a CTL assay at an E:T ratio of 5:1 or
applied to stimulate the CTL clone (1980-1) in an enzyme-linked immunospot assay. A plus indicates gamma interferon (IFN-) production by
the CTL clone, while a minus indicates no production of IFN-. Influenza virus (Resvir-9)-infected BLCL cells and uninfected BLCL cells were
included in both assays as positive and negative controls, respectively. Percent lysis is given as the mean  standard deviation, and the results are
representative of multiple experiments.
TABLE 1. Variation in HLA-B35-restricted influenza A virus
epitope NP418-426
Sequencea Yr(s) of isolation Virus subtype No. ofvirusesb Epitope name
LPFDRPTIM Before 1933 H1N1 1
–––––T––– 1934 H1N1 1
––––KT––– 1940–1957 H1N1/H2N2 6
––––K–––– 1957–1972 H2N2/H3N2 7 NP418-426/1957
––––KS––– 1972–1978 H3N2 12 NP418-426/1972
––––KS-V- 1977 H3N2 1
–––EKS––– 1983 H3N2 1
–––EKS-V- 1980–present H3N2 35 NP418-426/1980
a A dash indicates identity with amino acid at same position in first sequence.
b Number of viruses with the reported sequence in the influenza sequence
database (http://www.flu.lanl.gov). Influenza A viruses (H1N1) were excluded
from the analysis from 1977, the year that viruses of this subtype were reintro-
duced.
2568 NOTES J. VIROL.
dominant epitope. The mean frequency of NP418-426/1972-spe-
cific cells was much lower (1 in 16,226); however, one donor
exhibited a high number of NP418-426/1972-specific cells. For
the NP418-426/1957 epitope, low to undetectable numbers of
specific cells were detected.
Based on the prevalence of the sequences (Table 1), we
decided to focus on the NP418-426/1980, NP418-426/1972, and
NP418-426/1957 epitopes. Since mutations in the NP418-426
epitope emerged in an evolutionary fashion, we speculated that
CTL immunity directed against these epitopes was the basis for
the selection and/or emergence of mutant viruses. To test this
hypothesis, more T-cell clones were raised against historic (A/
Victoria/3/75) and recent (Resvir-9) viruses by using PBMC
from HLA-B35 donors obtained in the year 2001. CTL clone
1972-1 directed against the NP418-426/1972 epitope failed to
recognize the NP418-426/1980 epitope (Fig. 2A). Similarly, three
out of five CTL clones (1980-1, 1980-4, and 1980-5) directed
against the NP418-426/1980 epitope failed to react with the
NP418-426/1957 and NP418-426/1972 epitopes (Fig. 2C; also data
not shown). With the other two CTL clones (1980-2 and 1980-
3), some cross-reactivity was observed with the epitopes in
older influenza A virus strains (Fig. 2B; also data not shown).
The absence of recognition of the NP418-426/1980 epitope by
CTLs directed against older variants was also demonstrated
with PBMC obtained from two donors stimulated in vitro with
influenza virus A/Victoria/3/75 (Fig. 3E; also data not shown).
These PBMC did, however, recognize the homologous
NP418-426/1972 epitope. PBMC of some donors displayed
cross-reactivity with both variants after stimulation with A/Vic-
toria/3/75 or Resvir-9 (Fig. 3). This cross-reactivity can be
explained by the expansion of cross-reactive CTLs in PBMC, a
phenomenon previously described in C57BL/10 mice infected
with different strains of influenza A virus (15). Finally, one
donor (donor 5017) did not respond at all after stimulation
with A/Victoria/3/75 (Fig. 3C).
To exclude the influence of consecutive natural infections
with various influenza A viruses on the NP418-426-specific CTL
response, we obtained HLA-A2 HLA-B35 PBMC cryopre-
served between the years 1982 and 1984. Since this occurred
shortly after the introduction of the NP418-426/1980 variant
epitope, the chance of an infection with an NP418-426/1980
variant virus in these donors was relatively small. The
NP418-426/1980 epitope was not recognized by the PBMC of
these donors (donors 1 and 2) (Fig. 4) after stimulation with
both a recent strain of influenza virus (Resvir-9) and A/Victo-
ria/3/75, which contained the NP418-426/1972 epitope. The lack
of NP418-426/1980-specific activity was not caused by the ab-
sence of virus-specific CTL activity, since the NP418-426/1972
variant epitope and the conserved HLA-A*0201-restricted
M158-66 epitope were recognized.
Based on these findings, we argue that in addition to the
variation in the HLA-B8- and HLA-B*2705-restricted
epitopes, NP380-388 and NP383-391, respectively, the variation in
TABLE 2. Binding affinity of NP418-426 peptide to HLA-B*3501






a Capacity of binding to HLA-B*3501 is expressed as the concentration (mi-
cromolar) of peptide able to inhibit binding of the fluorescein isothiocyanate-
labeled reference peptide by 50% (32) based on two assays.
b HLA-B35-restricted influenza virus epitope from the matrix protein with a
reported low binding affinity (10).
TABLE 3. NP418-426 peptide-specific CTL frequencies in PBMC
Donor no.
Frequency of peptide-specific CTL
NP418-426/1980 NP418-426/1972 NP418-426/1957
5017 1/1,885 1/17,921 —a
5972 1/4,073 1/5,054 1/86,550
2384 1/15,485 1/17,329 1/10,108
5991 1/7,542 1/24,600 1/24,600
Mean 1/7,246 1/16,226 1/40,419
a No specific spots detected.
FIG. 2. NP418-426 variant epitope specificity of CTL clones. Target
cells (BLCL) were incubated overnight with 5 M concentrations of
the HLA-B*3501-restricted NP418-426 epitope variants, namely,
NP418-426/1980 (ƒ), NP418-426/1972 (), and NP418-426/1957 (}), or
were left untreated (F) and used as a negative control. Clones 1972-1
(A), 1980-2 (B), and 1980-4 (C), obtained from different donors, were
added at different effector-to-target cell ratios, and specific lysis was
calculated. The results, given as the percent specific lysis (mean 
standard deviation), are representative of multiple assays.
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this newly identified HLA-B*3501-restricted NP418-426 epitope
is driven by CTL immunity, leading to escape from recognition
by these CTLs. The variations in the NP380-388 and NP383-391
epitopes were found at the anchor residues (R384G mutation)
of the respective 9-mers (34). In the NP418-426 epitope, the
anchor residues for binding to HLA-B35 were perfectly con-
served in all virus strains isolated and sequenced since 1933. It
can be speculated that variation at these residues is restricted
by functional constraints. For example, an R267A mutation
within an HLA-A3-restricted epitope has been shown to affect
RNA binding by NP (11). Since the NP of A/Hong Kong/2/68,
containing the NP418-426/1957 epitope, and the NP of A/Neth-
erlands/18/94, containing the NP418-426/1980 epitope, function
equally well (34) and both viruses grow to comparable titers, it
is unlikely that the mutations in the NP418-426 epitope were
selected based on the improved fitness of these viruses.
HLA-B35-positive individuals constitute a significant por-
tion of the human population, ranging from 5% in Orientals to
10% in Caucasians (21). The immune pressure mediated by
CTLs in these individuals recognizing the NP418-426 epitope
may have contributed to the emergence of escape mutant vi-
ruses from the quasi species of influenza viruses and their
continued circulation. As a result of the immunodominant
nature of the epitope, the CTL response might have been
oligoclonal in HLA-B35 individuals, allowing for the selec-
tion of mutant viruses. Alternatively, other unknown epitopes
may overlap with NP418-426, further contributing to the selec-
tion pressure. The variants are maintained in HLA-B35-nega-
FIG. 3. Epitope specificity of the polyclonal response following in vitro stimulation of PBMC cryopreserved in the year 2001 with influenza A
viruses (H3N2) containing different variants of the epitope. PBMC of HLA-B35 donors, aged between 30 and 50 years, were stimulated in vitro
with A/Victoria/3/75 (A, C, and E), containing the NP418-426/1972 variant, or Resvir-9 (B, D, and F), containing the NP418-426/1980 epitope, as
described previously (3). After 8 days, the effector cells were tested for lytic activity against target cells incubated with the peptides corresponding
to NP418-426/1980 (ƒ), NP418-426/1972 (), and NP418-426/1957 (}). Untreated target cells (F) were included in each assay as a negative control.
Mean percentages of specific lyses of two independently repeated experiments are shown for donors 5972 (A and B), 5017 (C and D), and 5991
(E and F).
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tive individuals because the mutations in the NP418-426 epitope
did not reduce the fitness of these viruses. It is of interest that
the infection of mice transgenic for a single T-cell receptor
(TCR) specific for the H-2Db-restricted NP366-374 epitope of
influenza A virus resulted in the emergence of viruses contain-
ing amino acid mutations in this epitope, which impaired the
presentation of viral peptides by MHC class I molecules or
interfered with T-cell receptor recognition (27). Other muta-
tions at nonanchor residues have been described only for spo-
radic virus isolates, and their effect on T-cell recognition was
not studied (24). A mutation in a CTL epitope (NS1122-130) in
the (not naturally occurring) high-yield vaccine strain of influ-
enza virus A/Texas/36/91 (31) inhibited recognition by a CTL
clone. Other mechanisms based on mutations in CTL epitopes
contributing to reduction or elimination of CTL recognition
have been described, like “original antigenic sin” (18), antag-
onism (16, 17), and anergy. Although original antigenic sin and
anergy were not investigated in great detail, in one of the
PBMC samples, obtained in 1982, a response was found that
was specific for the NP418-426/1972 epitope but not for the
homologous NP418-426/1980 epitope used for stimulation.
In conclusion, a new variable CTL epitope was identified in
the NPs of influenza A viruses. Epidemiological and immuno-
logical evidence indicates that the variation found in this
epitope was the result of antigenic drift resulting from immune
pressure mediated by specific CTLs. Thus, in addition to the
introduction of mutations in the surface glycoproteins, which
allows for escape from antibody-mediated immunity, further
evidence which shows that influenza viruses can escape from
CTL-mediated immunity is accumulating. This would make
these viruses masters in disguise, partially explaining their rel-
ative success in infecting a large portion of the human popu-
lation every year for the past several decades.
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